Empagliflozin for the treatment of Type 2 diabetes.

about

Update on developments with SGLT2 inhibitors in the management of type 2 diabetes Short commentary on empagliflozin and its potential clinical impact Efficacy and safety of empagliflozin in type 2 diabetes mellitus: a meta-analysis of randomized controlled trials.

P2860

Q34198692-5EE129CE-1B87-4926-9ADC-95B69D73F891 Q35528797-BF4939CD-3F14-465D-98C0-30AE11B4890A Q39007677-4C2466B4-7E1F-40E3-82EB-A4229DCAC5AB

P2860

Empagliflozin for the treatment of Type 2 diabetes.

Item

http://www.wikidata.org/entity/Q38203327

description

article científic

@ca

article scientifique

@fr

articol științific

@ro

articolo scientifico

@it

artigo científico

@gl

artigo científico

@pt

artigo científico

@pt-br

artikel ilmiah

@id

artikull shkencor

@sq

artículo científico

@es

name

Empagliflozin for the treatment of Type 2 diabetes.

@en

type

Item

label

Empagliflozin for the treatment of Type 2 diabetes.

@en

prefLabel

Empagliflozin for the treatment of Type 2 diabetes.

@en

P1476

Empagliflozin for the treatment of Type 2 diabetes.

@en

P2093

Amanda Mather

http://www.w3.org/2001/XMLSchema#string

P2860

Effect of Rosiglitazone on the Risk of Myocardial Infarction and Death from Cardiovascular Causes

Active sugar transport in health and disease

Saxagliptin and cardiovascular outcomes in patients with type 2 diabetes mellitus

Global estimates of the prevalence of diabetes for 2010 and 2030

Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes

Effects of intensive glucose lowering in type 2 diabetes

Why Do SGLT2 inhibitors inhibit only 30-50% of renal glucose reabsorption in humans?

Empagliflozin, a novel selective sodium glucose cotransporter-2 (SGLT-2) inhibitor: characterisation and comparison with other SGLT-2 inhibitors.

SGLT2 mediates glucose reabsorption in the early proximal tubule.

Glucose transport by human renal Na+/D-glucose cotransporters SGLT1 and SGLT2.

P304

271-279

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1586/17512433.2014.908703

http://www.w3.org/2001/XMLSchema#string

P407

English

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P50

Muralikrishna Gangadharan Komala

P577

2014-04-09T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

24716752

http://www.w3.org/2001/XMLSchema#string

P921

type-2 diabetes

empagliflozin

Empagliflozin for the treatment of Type 2 diabetes.

about

P2860

P2860

Empagliflozin for the treatment of Type 2 diabetes.

description

name

type

label

prefLabel

P1433

P1476

P2093

P2860

P304

P31

P356

P407

P433

P478

P50

P577

P698

P921

P356

P1433

P1476

P2093

P2860

P304

P31

P356

P407

P433

P478

P50

P577

P698

P921